These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 20732960)

  • 21. Association of skin rash and tumor response to HER1/EGFR inhibition: does HER1 stimulated tumor growth depend on circulatory instead of paracrine ligands?
    Kurbel S; Faj D
    Med Hypotheses; 2005; 64(6):1244-5. PubMed ID: 15823732
    [No Abstract]   [Full Text] [Related]  

  • 22. Clinical research of EGFR inhibitors and related dermatologic toxicities.
    Perez-Soler R; Van Cutsem E
    Oncology (Williston Park); 2007 Oct; 21(11 Suppl 5):10-6. PubMed ID: 18154213
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Therapies directed against epidermal growth factor receptor in aerodigestive carcinomas.
    Karamouzis MV; Grandis JR; Argiris A
    JAMA; 2007 Jul; 298(1):70-82. PubMed ID: 17609492
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Temporal dependence of the effect of radiation on erlotinib-induced skin rash.
    Lacouture ME; Hwang C; Marymont MH; Patel J
    J Clin Oncol; 2007 May; 25(15):2140; author reply 2141. PubMed ID: 17513824
    [No Abstract]   [Full Text] [Related]  

  • 25. Sparing of previously irradiated skin from erlotinib-induced acneiform rash.
    Yalçin S; Dizdar O; Yalçin B; Gököz O
    J Am Acad Dermatol; 2008 Jan; 58(1):178-9. PubMed ID: 18158935
    [No Abstract]   [Full Text] [Related]  

  • 26. Does sunscreen prevent epidermal growth factor receptor (EGFR) inhibitor-induced rash? Results of a placebo-controlled trial from the North Central Cancer Treatment Group (N05C4).
    Jatoi A; Thrower A; Sloan JA; Flynn PJ; Wentworth-Hartung NL; Dakhil SR; Mattar BI; Nikcevich DA; Novotny P; Sekulic A; Loprinzi CL
    Oncologist; 2010; 15(9):1016-22. PubMed ID: 20798191
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Phase I-IIa study of BMS-690514, an EGFR, HER-2 and -4 and VEGFR-1 to -3 oral tyrosine kinase inhibitor, in patients with advanced or metastatic solid tumours.
    Soria JC; Baselga J; Hanna N; Laurie SA; Bahleda R; Felip E; Calvo E; Armand JP; Shepherd FA; Harbison CT; Berman D; Park JS; Zhang S; Vakkalagadda B; Kurland JF; Pathak AK; Herbst RS
    Eur J Cancer; 2013 May; 49(8):1815-24. PubMed ID: 23490650
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Phase II study of erlotinib in patients with advanced biliary cancer.
    Philip PA; Mahoney MR; Allmer C; Thomas J; Pitot HC; Kim G; Donehower RC; Fitch T; Picus J; Erlichman C
    J Clin Oncol; 2006 Jul; 24(19):3069-74. PubMed ID: 16809731
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Epidermal growth factor receptor inhibition strategies in oncology.
    Harari PM
    Endocr Relat Cancer; 2004 Dec; 11(4):689-708. PubMed ID: 15613446
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Correlation between efficacy and skin rash occurrence following treatment with the epidermal growth factor receptor inhibitor cetuximab: a single institution retrospective analysis.
    Orditura M; De Vita F; Galizia G; Lieto E; Vecchione L; Vitiello F; Martinelli E; Ciardiello F
    Oncol Rep; 2009 Apr; 21(4):1023-8. PubMed ID: 19288004
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Nursing management of epidermal growth factor receptor inhibitor-induced toxicities.
    Dunsford J
    Clin J Oncol Nurs; 2008 Jun; 12(3):405-7. PubMed ID: 18515238
    [No Abstract]   [Full Text] [Related]  

  • 32. Clinical breakthroughs in EGFR inhibition: applying the science to your clinical practice.
    Morse L
    ONS News; 2006; 21(8 Suppl):59-60. PubMed ID: 16925155
    [No Abstract]   [Full Text] [Related]  

  • 33. Targeting the epidermal growth factor receptor in colorectal carcinoma.
    Kurtin SE
    Cancer Nurs; 2007; 30(4 Suppl 1):S1-9. PubMed ID: 17666985
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Trichomegaly of the eyelashes during therapy with epidermal growth factor receptor inhibitors: report of 3 cases.
    Fabbrocini G; Panariello L; Cacciapuoti S; Bianca D; Ayala F
    Dermatitis; 2012; 23(5):237-8. PubMed ID: 23010833
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Concurrent erlotinib and radiotherapy for chemoradiotherapy-intolerant esophageal squamous cell carcinoma patients: results of a pilot study.
    Zhai Y; Hui Z; Wang J; Zou S; Liang J; Wang X; Lv J; Chen B; Zhu H; Wang L
    Dis Esophagus; 2013 Jul; 26(5):503-9. PubMed ID: 22862289
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Characterisation of the cutaneous pathology in non-small cell lung cancer (NSCLC) patients treated with the EGFR tyrosine kinase inhibitor erlotinib.
    Guttman-Yassky E; Mita A; De Jonge M; Matthews L; McCarthy S; Iwata KK; Verweij J; Rowinsky EK; Krueger JG
    Eur J Cancer; 2010 Jul; 46(11):2010-9. PubMed ID: 20621734
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Phase I study of cetuximab, erlotinib, and bevacizumab in patients with advanced solid tumors.
    Lin CC; Calvo E; Papadopoulos KP; Patnaik A; Sarantopoulos J; Mita AC; Preston GG; Mita MM; Rodon J; Mays T; Yeh IT; O'Rourke P; Takimoto CH; Dancey JE; Chen H; Tolcher AW
    Cancer Chemother Pharmacol; 2009 May; 63(6):1065-71. PubMed ID: 18795291
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Dual inhibition of the epidermal growth factor receptor with cetuximab, an IgG1 monoclonal antibody, and gefitinib, a tyrosine kinase inhibitor, in patients with refractory non-small cell lung cancer (NSCLC): a phase I study.
    Ramalingam S; Forster J; Naret C; Evans T; Sulecki M; Lu H; Teegarden P; Weber MR; Belani CP
    J Thorac Oncol; 2008 Mar; 3(3):258-64. PubMed ID: 18317068
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Higher severity grade of erlotinib-induced rash is associated with lower skin phototype.
    Luu M; Boone SL; Patel J; Sullivan P; Rademaker AW; Balagula Y; Lacouture ME
    Clin Exp Dermatol; 2011 Oct; 36(7):733-8. PubMed ID: 21689147
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Description and management of cutaneous side effects during cetuximab or erlotinib treatments: a prospective study of 30 patients.
    Roé E; García Muret MP; Marcuello E; Capdevila J; Pallarés C; Alomar A
    J Am Acad Dermatol; 2006 Sep; 55(3):429-37. PubMed ID: 16908348
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.